市場調查報告書
商品編碼
1494599
全球醫用針市場評估:依針類型、依產品類型、依交付地點、依材料類型、依應用、依最終用戶、依地區、機會、預測(2017-2031)Medical Needles Market Assessment, By Needle Type, By Product Type, By Delivery Site, By Material Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
全球醫用針頭市場規模預計將從 2023 年的 80.4 億美元增至 2031 年的 133.3 億美元,預計 2024-2031 年複合年增長率為 6.52%。全球慢性病和生活方式問題的發生率不斷上升,預計將推動針業的顯著成長。標準皮下注射針通常稱為常規針,是各種醫療應用中使用最廣泛的針類型。這包括注射藥物和疫苗,以及取出用於測試的血液樣本等體液。
傳統針頭和安全針頭之間的主要區別在於,傳統針頭雖然有效,但沒有內建安全功能來避免使用後針刺傷。安全針旨在防止針刺傷,以免將感染傳播給患者和醫護人員。這些過程可以由醫療保健專業人員手動觸發,也可以在註射後自動觸發。外科手術的增加預計將繼續推動縫合針的需求。隨著人口老化變得更容易感染許多疾病,全球注射器針頭市場預計將會成長。加強疫苗接種活動將促進針頭銷售,特別是在發展中國家。此外,人們越來越認識到注射劑對成功治療的重要性,也推動了針頭的接受度不斷提高。然而,有關針頭安全和設計的嚴格法律可能會限制該行業的擴張。
例如,醫療設備製造商 Rhythmlink International, LLC 於 2023 年 10 月 13 日發佈的最新產品線 Concentric Needles。依照核准的程序,同心針有四種尺寸或規格,具有不同的針直徑、長度和顏色。
藥物傳遞的進步推動市場成長
藥物輸送的發展是推動醫用針頭市場發展的重大機會。隨著製藥業的發展,以患者為中心、優先考慮使用者舒適性、安全性和便利性的設計變得更加重要。新的藥物輸送技術(例如改進的注射器、自動注射器和筆式註射器)極大地影響了針頭的需求。自動注射器特別常用於治療長期疾病,例如多發性硬化症、類風濕性關節炎和需要腎上腺素的嚴重過敏反應。自動注射器可讓您自行注射預先定量的藥物。它的易用性鼓勵患者遵守規定的時間表,使他們能夠更好地控制醫療保健的管理方式。同樣,經常用於注射胰島素以治療糖尿病的筆式註射器方便攜帶且易於使用,使患者更容易注射。筆式註射器通常使用短而細的針頭,即使注射少量也無痛,這與目前醫療向微創治療的發展方向一致。
雖然預充式註射器提供便利並減少藥物浪費,但安全注射器具有可最大限度減少針刺傷害的安全功能。由於生物相似藥和生物製劑市場的不斷擴大,基於針頭的藥物輸送系統越來越受歡迎。由於生物製劑的複雜性和穩定性要求,必須透過注射輸送,因此需要能夠處理高黏度製劑而不犧牲患者舒適度的專用針頭。針頭行業的製造商應與製藥公司和醫療保健專業人員密切合作,以利用此機會。他們還必須滿足嚴格的品質要求,支援最新的藥物輸送系統,並改善整體患者體驗。藥物輸送設備的創新響應了當前的市場需求並預測了新的趨勢。因此,在發明和競爭日益激烈的醫療領域,此類改進可確保針製造商的持續成長和市場佔有率。例如,全球合約研究、開發和製造組織 (CRDMO) 藥明生物製品有限公司於 2022 年 6 月開始在中國無錫依照 GMP 運營一家新的製藥廠 DP5。該設施提供具有多種劑量輸送選項的預充式註射器 (PFS)。
本報告研究和分析了全球醫用針市場,提供市場規模和預測、市場動態以及主要參與者的現狀和前景。
Global medical needles market is projected to witness a CAGR of 6.52% during the forecast period 2024-2031F, growing from USD 8.04 billion in 2023 to USD 13.33 billion in 2031F. Globally increasing rates of chronic illness and lifestyle issues are predicted to drive significant growth in the needle industry. Standard hypodermic needles, commonly called conventional needles, are the most widely used kind of needles for various medical applications. It includes injectable drug and vaccine administration and removal of bodily fluids, such as blood samples for testing.
The main difference between conventional and safety needles is that, although effective, conventional needles lack built-in safety features to avoid needle stick injuries after usage. With incorporated safety measures, safety needles are intended to prevent needle stick injuries, which can spread infectious diseases in patients and healthcare personnel. The healthcare professionals can manually engage these processes, or they can be activated automatically after the injection. Demand for suturing needles will continue to be driven by an increase in surgical operations. The worldwide needle market is predicted to grow due to increased susceptibility of aging population to numerous illnesses. Increasing immunization campaigns will boost injection needle sales, particularly in developing countries. Moreover, increased acceptance of the needles is probably due to growing recognition of the significance of therapeutic injectables for successful therapy. Strict laws governing needle safety and design, however, can restrain industry expansion.
For instance, Concentric needles, a recent product family introduced by medical device manufacturer Rhythmlink International, LLC on October 13, 2023. In accordance with the approved procedures, the concentric needle is available in four sizes or gauges, which differ in needle diameter, length, and color.
Advancements in Drug Delivery to Propel Market Growth
Developments in drug delivery provide a substantial chance to propel the medical needle market forward. As the pharmaceutical industry develops, patient-centric designs which put comfort, safety, and convenience of the users first, are becoming more important. The requirement for needles is being significantly impacted by new drug delivery technologies such as improved syringes, auto-injectors, and pen injectors. Auto-injectors are especially well-adopted for long-term conditions like multiple sclerosis, rheumatoid arthritis, and severe allergic reactions that call for epinephrine. They enable self-administration of premeasured dosages of medication. The ease of use encourages patients to follow their prescription schedules and gives them more control over how their healthcare is managed. Similarly, pen injectors, which are frequently used to provide insulin for the management of diabetes are made portable and easy to use, making use of injections easier for patients. They frequently call for kinds of needles which are short, thin, and less painful for little doses, which is consistent with the current movement in medicine towards less invasive treatments.
Prefilled syringes offer convenience and less pharmaceutical waste, but safety syringes feature built-in safety, safeguarding to minimize needle stick injuries. Needle-based medication delivery systems are becoming more popular due to growing markets for biosimilars and biologics. Since biologics must be supplied by injection due to their complexity and stability requirements, specialized needles that can handle high-viscosity formulations without sacrificing patient comfort are required. Manufacturers in the needle industry need to work closely with pharmaceutical companies and healthcare professionals to take advantage of the opportunity. They need to make sure that their goods fulfill strict quality requirements, work with the newest medicine delivery systems, and improve the patient experience in general. Drug delivery device innovations respond to current market demands and foresee emerging trends. Therefore, in an increasingly inventive and competitive healthcare sector, these improvements can ensure continued growth of needle producers and market presence. For instance, the global contract research, development, and manufacturing organization (CRDMO) WuXi Biologics Co., Ltd. started operating its new pharma product facility, DP5, in Wuxi, China, under Good Manufacturing Practices (GMP) in June 2022. The facility provides pre-filled syringes (PFS) with a variety of volume delivery options.
Advancements in Needle Technology to Drive the Market Growth
The medical needle market is anticipated to be significantly driven by developments in needle technology. The goals of recent technological advancements have been made to minimize tissue harm, increase patient comfort, and lessen pain. These developments are significant elements that will probably encourage the use of sophisticated needles in a range of medical settings. The development of safety needles, which are intended to lower needle stick injuries among medical personnel, is one such improvement. To minimize unintentional injury, these needles have safety features which retract, cover, or blunt the needle after usage.
The creation of ultra-fine needles which are less painful is another inventive innovation. These are especially helpful for individuals who need injections frequently, including diabetics who need to periodically check their insulin levels. The development of needles with specific coatings that enable smoother entry into the skin and lower friction, hence improving patient comfort, has attracted a lot of interest. The needle sector has an excellent opportunity for expansion due to microneedle technology. Micro needles are tiny needles that can be inserted subcutaneously to administer medications or immunizations without causing pain. The technology could enhance the way vaccines are administered and broaden the range of medications for self-consumption, which would make treatment more convenient for patients. Improvements in needle technology is intended to enhance the patient experience and drug adherence by reducing injection-related discomfort. It is important to know while managing chronic diseases since patients may not want to follow treatment plans that require numerous needle sticks. Overall, the worldwide needle market is anticipated to grow rapidly as needle technology advances with characteristics that support safety, comfort, and efficacy, better satisfying the needs of patients and healthcare providers. For instance, Serpex Medical Inc. announced in September 2022 that the Compass Steerable Needles, steerable biopsy needles which allow for accurate access to lung lesions in the intrapulmonary region to enhance lung cancer diagnosis and therapy, had received U.S. FDA 510(k) clearance. The Recon Steerable Sheath must be cleared before removing the compass steerable needles.
Increasing Dominance of Insulin Administration Bolsters Market Growth
The rising prevalence of diabetes significantly drives the expansion of global medical needles market. Diabetes management often requires regular blood glucose monitoring and insulin administration, which involves the frequent usage of medical needles. As the number of diabetes patients increases globally, there is a corresponding rise in demand for insulin pens, syringes, and lancets. The trend is particularly pronounced in regions experiencing rapid lifestyle changes and urbanization, which contributes to the growing incidence of diabetes.
Furthermore, advancements in needle technology, such as the development of fine-gauge needles which minimize discomfort, have enhanced patient compliance and the overall adoption of insulin therapy. These technological improvements cater to the needs of diabetic patients, making self-administration more convenient and less painful. Additionally, increased awareness and early diagnosis of diabetes have led to more consistent use of medical needles for blood glucose testing and insulin delivery. For instance, Accu-Fine, premium pen needles were introduced in May 2022 by Roche Diabetes Care (F. Hoffmann-La Roche Ltd), a leader in the world of integrated personalized diabetes management (iPDM), to help diabetics administer insulin more smoothly and almost painlessly. The goal of this recent invention from Roche Diabetes Care, the company that makes Accu-Chek, was to simplify the insulin delivery procedure for diabetics, improving their ability to manage their condition.
North America to Dominate the Global Medical Needles Market Share
Due to the size of the United States market, North America is anticipated to dominate the global medical needles market. The rising incidence of diabetes, growing prevalence of heart problems, and numerous innovative product approvals in the region are the main drivers propelling the growth of needles market in North America. According to the report of Centers for Disease Control and Prevention, published in July 2022, about 805,000 Americans suffered from heart attacks annually. The most prevalent kind of heart disease, coronary artery disease, affects more than 20.1 million people in the country over the age of 20.
Syringes and needles are necessary for CVD treatments and therapies. Therefore, it is anticipated that the high disease prevalence will aid in the market's expansion. Additionally, the country has a high and rising incidence of diabetes. Syringes and insulin pens are used in the treatment of diabetes. Therefore, rising diabetes prevalence indicates the market expansion. The examined market is expanding as a part of the latest product approvals in the region. For instance, the TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe (PFS) was approved by the US Food and Drug Administration in February 2022 by Takeda Pharmaceutical Company Limited to prevent attacks of hereditary angioedema (HAE). It is anticipated that these factors will support regional market expansion.
Future Market Scenario (2024 - 2031F)
One of the main factors contributing to the anticipated growth of the needles market is the increasing prevalence of chronic disorders, such as cancer and diabetes, and increasing popularity of minimally invasive surgical procedures. A rising population and sedentary lifestyles are factors that will propel the market growth in future. As technology is advancing, we can expect cutting-edge technology in the region. Players in the market are expanding at an unparalleled rate, introducing cost-effective and efficient technologies. For instance, Broncus Medical Inc. made an announcement in September 2023 regarding the release of a novel transbronchial needle intended for less invasive diagnostic uses.
The Wellcome Foundation awarded Vaxxas Pty. Ltd. with USD 3.7 million in August 2023 to further develop needle-free typhoid vaccination technology.
Key Players Landscape and Outlook
Several companies are expanding their business by planning and adopting new strategies. They are complying with new strategic initiatives regarding the launch of newly developed medical needles, to help researchers and expand their presence in the market. Product launches, agreements based on contracts, acquisitions and mergers, investments, and partnerships are some through which they are trying to achieve a larger market share.
On September 26, 2023, Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. announced the signing of an Asset Purchase Agreement (APA) to acquire Nephron's InjectEZ specialty syringe manufacturing facility. It includes an agreement to buy next-generation copolymer prefillable syringe systems from Nephron Pharmaceuticals for more than USD 400 million.
The medical equipment manufacturer ICU Medical Inc. announced in January 2022 that it was purchasing Smiths Medical. Vascular access, vital care products, syringe, and mobile infusion devices which are part of the Smiths Medical company.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.